Human medicines European public assessment report (EPAR): Kadcyla, trastuzumab emtansine, Date of authorisation: 15/11/2013, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Date of authorisation: 27/06/2025, Revision: 2, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Startvac, adjuvanted inactivated vaccine for cattle against Staphylococcus aureus, coliforms and coagulase-negative staphylococci, Status: Authorised

Human medicines European public assessment report (EPAR): Lonquex, lipegfilgrastim, Date of authorisation: 25/07/2013, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Palsonify, paltusotine, Date of authorisation: 23/04/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Date of authorisation: 22/05/2014, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rezzayo, rezafungin, Date of authorisation: 22/12/2023, Revision: 4, Status: Authorised